European Commission Approves Mosunetuzumab for Patients with R/R Follicular Lymphoma - Targeted Oncology
The European Commission has granted a conditional marketing authorization to mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 prior systemic therapies
Conditional marketing authorization has been granted to the CD20xCD3 T-cell engaging bispecific antibody mosunetuzumab (Lunsumio) by the European Commission for the treatment of adult patients with r… [+6886 chars]
Read More
Other Stories in Business
- Gulf War veteran executed for 1998 quadruple murder despite claims of mental illness
- Guardant Health (GH) Reports Strong Q1 2025 Revenue Growth
- Connecting Asia's startup ecosystem
- Connecting Asia's startup ecosystem
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- Business First Bancshares, Inc. (BFST) Q1 2025 Earnings Call Transcript
